Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. developed cell therapies and immunotherapies for cancer and other incurable diseases, with company news centered on anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Coverage included clinical data from the iMMagine program, scientific presentations on the D-Domain binder, and collaboration activity with Kite, a Gilead company.
Arcellx became a wholly owned subsidiary of Gilead Sciences after the completed acquisition in 2026, and its common stock was delisted from the Nasdaq Global Select Market. Later company developments therefore include the completed transaction, shareholder-related deal coverage, capital-structure matters, and public-company status changes.
Gilead Sciences (Nasdaq: GILD) completed its acquisition of Arcellx (Nasdaq: ACLX) on April 28, 2026, buying Arcellx for $115 cash per share plus one $5 CVR, implying approximately $7.8 billion equity value.
The CVR pays if cumulative global net sales of anito-cel reach $6.0 billion through 2029. Arcellx becomes a Gilead subsidiary and its common stock will be delisted. Gilead expects 2026 diluted EPS to decline by $5.57–$5.67 and forecasts modest dilution in 2026–2027, with accretion in 2028+ subject to FDA approval of anito-cel.
Gilead Sciences (Nasdaq: GILD) agreed to acquire Arcellx (Nasdaq: ACLX) for $115 per share cash plus a $5 CVR, implying an equity value of $7.8 billion. The deal carries a 68% premium to Arcellx’s 30‑day VWAP and is expected to close in Q2 2026, subject to tender and regulatory approvals.
The acquisition gives Gilead full control of anito-cel, whose BLA was accepted by FDA with a PDUFA date of Dec 23, 2026, and is expected to be accretive to EPS in 2028 if approved.
Arcellx (NASDAQ: ACLX) will present late-breaking preclinical data on February 5, 2026 at the Tandem Meetings showing its D-Domain binder in anitocabtagene autoleucel (anito-cel) lacked tonic signaling and Claudin-9 cross-reactivity in head-to-head CAR constructs versus dual VHH and scFv binders.
Results showed dual VHH (cilta-cel-like) exhibited tonic signaling and CLDN9 off-target activity, while the D-Domain and scFv did not, supporting a differentiated target-specificity and favorable safety profile for anito-cel.
Arcellx (NASDAQ: ACLX) will present three research abstracts at the 2026 Tandem Meetings (Feb 4-7, 2026) in Salt Lake City on its D-Domain platform and anito-cel for multiple myeloma. One presentation describes the D-Domain binder's fast off-rate and a mechanistic rationale for anito-cel’s differentiated pharmacology. A simulation model reports using CAR T before bispecific antibodies in 4L+ RRMM could lower risk of progression or death by 64% and death by 48% over five years versus the reverse sequence. A separate study highlights geographic inequities in CAR T access, noting long travel and out-of-state care that suggest referral gaps and ATC expansion needs. Anito-cel is partnered with Kite, a Gilead Company.
Arcellx (NASDAQ: ACLX) reported updated pivotal Phase 2 iMMagine-1 results for anitocabtagene autoleucel (anito-cel) in 117 relapsed/refractory multiple myeloma patients with a median follow-up of 15.9 months (data cutoff Oct 7, 2025).
Key efficacy: ORR 96%, CR/sCR 74%, ≥VGPR 88%; MRD negativity 95% (91/96) and sustained MRD negativity >6 months 83% (54/65) at 10-5 sensitivity. Timepoint survival: 12‑month PFS/OS 82.1%/94.0%, 18‑month PFS/OS 67.4%/88.0%, 24‑month PFS/OS 61.7%/83.0%.
Safety: no delayed or non‑ICANS neurotoxicities observed to date (all patients dosed ≥12 months). Company reiterates planned 2026 commercial launch. Data presented at ASH on December 6, 2025.
Arcellx (NASDAQ: ACLX) will host an Investor Relations event on Saturday, December 6, 2025 at 8:00 p.m. ET in Redwood City.
The session will feature a panel of clinician experts and a discussion of the latest data from the company’s Phase 2 pivotal iMMagine-1 study in patients with relapsed or refractory multiple myeloma. A live webcast will be accessible from Arcellx's Investors website and a replay will be archived and available for 30 days after the event.
Arcellx (NASDAQ: ACLX) reported third quarter 2025 results for the period ended September 30, 2025. Key financials: $576.0 million in cash, cash equivalents, and marketable securities; company expects these funds to support operations into 2028. Collaboration revenue fell to $4.9 million from $26.0 million, largely due to completion of dosing and manufacturing of anito-cel in iMMagine-1 in Q4 2024. R&D expense decreased to $35.1 million while G&A rose to $31.6 million. Net loss widened to $55.8 million from $25.9 million year-over-year.
Arcellx (NASDAQ: ACLX) will present updated clinical and preclinical data at the 67th ASH Annual Meeting (Dec 6-9, 2025) in Orlando. An oral presentation on iMMagine-1 (Phase 2 registrational study of anitocabtagene autoleucel) is scheduled for Dec 6, 2025 at 2:45 p.m. ET (publication #256).
The company said a more recent data cut will be shared, no delayed neurotoxicities (including Parkinsonism, cranial nerve palsies, Guillain-Barré, or immune effector cell-associated enterocolitis) have been observed to date, and a supplemental Blood publication on anito-cel’s D-Domain fast off-rate will appear in November 2025 (publication #7644). Arcellx reported a pre-BLA meeting with the FDA and reiterated a planned 2026 commercial launch.
Arcellx (NASDAQ:ACLX), a biotechnology company focused on innovative cell therapy and immunotherapies for cancer and incurable diseases, announced its upcoming participation in the 2025 Morgan Stanley Global Healthcare Conference.
The company's management will engage in a fireside chat on September 10, 2025 at 1:05 p.m. ET. Investors can access the live webcast through Arcellx's website, with a replay available for 30 days after the event.
Arcellx (NASDAQ: ACLX) reported Q2 2025 financial results and clinical progress. The company presented promising data from its Phase 2 pivotal iMMagine-1 study of anito-cel in relapsed/refractory multiple myeloma, showing a 97% overall response rate and 68% complete response rate among 117 patients.
Key clinical achievements include 93.3% minimal residual disease negativity in evaluable patients and strong survival rates, with no delayed neurotoxicities observed. The FDA cleared the IND application for ACLX-004 targeting CD33 and CD123.
Financially, Arcellx ended Q2 with $537.6 million in cash, expected to fund operations into 2028. The company reported a net loss of $52.8 million, with R&D expenses of $37.6 million and collaboration revenue of $7.6 million.